Results 221 to 230 of about 89,275 (314)

Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 3, March 2026.
ABSTRACT Machine learning (ML)–based methods have been proposed as a potential approach for identifying candidate drugs to be repurposed as disease‐modifying treatments for Parkinson's disease (PD). We applied an ML‐based signal detection method to identify drugs associated with PD and evaluated the method's generalizability.
Eeva Pylkkö, Émeline Courtois, Anne Paakinaho, Sirpa Hartikainen, Valtteri Kaasinen, Alexis Elbaz, Anne C. M. Thiébaut, Ismaïl Ahmed, Anna‐Maija Tolppanen   +8 more
wiley   +1 more source

Cognitive Outcomes of Children Exposed to Selective Serotonin Reuptake Inhibitors Through Breast Milk.

JAMA Netw Open
Heinonen EW, Kao K, Mattson SN, Chambers CD.   +3 more
europepmc   +1 more source

Selective serotonin reuptake inhibitors induce cardiac toxicity through dysfunction of mitochondria and sarcomeres. [PDF]

Commun Biol
Shen Y, Brown CE, Li X, Zhang P, McGee SR, Spina SC, Loret de Mola JR, Fiddler JL, Wu H, Liu Q.   +9 more
europepmc   +1 more source

Commentary: Beware regression to the mean [PDF]

, 2000
Cole, TJ
core  

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 545-555, February 2026.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

Progress in the study of the effects of selective serotonin reuptake inhibitors (SSRIs) on the reproductive system. [PDF]

Front Pharmacol
Feng Y, Qu X, Hao H.
europepmc   +1 more source

Selective Serotonin Reuptake Inhibitors and Cosmetic Psychopharmacology: Ethical and Deontological Dilemmas [PDF]

, 2004
DiPietro, Maria Luisa, Navarrini, Claudia, Spagnolo, Antonio G.   +2 more
core   +2 more sources

In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole resistant strains and their activity in biofilm forming isolates

, 2016
Rose Anny Costa Silva
openalex   +1 more source

Quantifying serotonin in four aquatic invertebrates using enzyme-linked immunosorbent assays (ELISA): implications for assessing selective serotonin reuptake inhibitor (SSRI) effects.

Lautrette-Quinveros, Harmony
openalex   +1 more source

From Struggling (With) Screening Tests to Mouse Models of Depression‐Relevant Neurobehavioral States

Current Protocols, Volume 6, Issue 2, February 2026.
Abstract A major, serendipitous psychiatric discovery is monoamine‐transporter reuptake inhibition as an antidepressant mechanism of action. Chronic treatment with such antidepressants is efficacious, with onset requiring 1‐2 weeks, in many but by no means all patients with major depressive or another stress‐related neuropsychiatric disorder.
Christopher R. Pryce
wiley   +1 more source